Strongbridge Biopharma plc to Present at the JMP Securities Life Sciences Conference
Strongbridge Biopharma plc
Jun. 06, 2018
DUBLIN, Ireland and TREVOSE, Pa., June 06, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that management will present at the JMP Securities Life Sciences Conference taking place June 20-21, 2018 at the St. Regis in New York, NY.
Matthew Pauls, president and chief executive officer of Strongbridge Biopharma, will provide a corporate overview on Wednesday, June 20 at 12:00p.m. E.T. The presentation will be webcast live and archived on the “Events & Presentations” page in the investor section of the Company’s website at www.strongbridgebio.com.
About Strongbridge Biopharma Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's commercial portfolio within its rare neuromuscular and rare endocrine franchises includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis, and MACRILEN™ (macimorelin), the first and only FDA-approved oral drug indicated for the diagnosis of adult growth hormone deficiency. The Company’s rare endocrine franchise also includes a clinical-stage pipeline of therapies: RECORLEV™ (levoketoconazole), a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome, and veldoreotide, a next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation.
Corporate and Media Relations Elixir Health Public Relations Lindsay Rocco +1 862-596-1304 firstname.lastname@example.org
Investor RelationsUnited States:Solebury Trout Marcy Nanus +1 646-378-2927 email@example.com
Europe:First HouseGeir Arne Drangeid +47 913 10 458 firstname.lastname@example.org
USA 900 Northbrook Drive Suite 200 Trevose, PA 19053 Tel. +1 610-254-9200 Fax. +1 215-355-7389